chronic hepatitis B
Hepatology · 2005–2017
16decisions
6medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tenofovir alafenamide Treatment of chronic hepatitis B infections in adult patients, both treatment-naïve and treatment-experienced, with or without cirrhosis. | Mar 2017 | Recommended with restriction | input received |
| tenofovir disoproxil fumarate Extension of listing to include treatment of HBeAg-negative, treatment-naïve patients and treatment-experienced patients with chronic hepatitis B (CHB). | Jul 2009 | Recommended with restriction | no section in document |
| telbivudine Treatment of chronic hepatitis B in patients who are nucleoside analogue naïve and HBeAg-positive, with compensated liver disease, evidence of viral… | Mar 2008 | Recommended with restriction | no section in document |
| tenofovir disoproxil fumarate Treatment of chronic hepatitis B in treatment-naïve patients with histological evidence of chronic hepatitis and abnormal serum ALT levels and/or elevated HBV… | Nov 2008 | Noted | no section in document |
| telbivudine Treatment of patients with chronic hepatitis B (HBeAg-positive and HBeAg-negative) who have compensated liver disease, evidence of viral replication, active… | Jul 2007 | Not recommended | no section in document |
| telbivudine Treatment of patients with chronic hepatitis B (HBeAg-positive and HBeAg-negative) who have compensated liver disease, evidence of viral replication, active… | Jul 2007 | Not recommended | no section in document |
| adefovir dipivoxil Extension of listing for patients with active chronic hepatitis B with advanced liver disease (cirrhosis or Child-Pugh-Turcotte score >5) or post-liver… | Mar 2007 | Recommended | no section in document |
| adefovir dipivoxil Chronic hepatitis B in patients who have failed antihepadnaviral therapy, specifically lamivudine-resistant patients, allowing concurrent use of adefovir with… | Nov 2007 | Recommended with restriction | no section in document |
| adefovir dipivoxil Chronic hepatitis B in patients who have failed antihepadnaviral therapy, for concurrent use with lamivudine in lamivudine-resistant patients. | Nov 2007 | Recommended with restriction | no section in document |
| adefovir dipivoxil Extension of listing for patients with active chronic hepatitis B to include treatment in combination with lamivudine of nucleoside therapy naïve patients with… | Jul 2006 | Not recommended | no section in document |
| adefovir dipivoxil Extension of listing for active chronic hepatitis B to include treatment in combination with lamivudine of nucleoside therapy naïve patients with advanced… | Jul 2006 | Not recommended | no section in document |
| entecavir Treatment of chronic hepatitis B in adults 16 years and older with evidence of active liver inflammation. Listing sought for nucleoside-naïve patients (500… | Jul 2006 | Recommended | no section in document |
| adefovir dipivoxil Extension of listing for patients with active chronic hepatitis B to include treatment in combination with lamivudine of nucleoside therapy naïve patients with… | Jul 2006 | Not recommended | no section in document |
| entecavir Treatment of chronic hepatitis B infection in adults aged 16 years and older with evidence of active liver inflammation. Listing sought for nucleoside-naïve… | Jul 2006 | Recommended with restriction | no section in document |
| peginterferon alfa-2a Treatment of chronic hepatitis B in patients with compensated liver disease, evidence of viral replication and liver inflammation, who have not received prior… | Nov 2005 | Recommended with restriction | no section in document |
| peginterferon alfa-2a Treatment of patients with chronic hepatitis B who have compensated liver disease, abnormal serum ALT levels, documented chronic hepatitis B infection (HBe… | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$202M in government benefit over 2024–25, across 329,141 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tenofovir alafenamide | $174.5M |
| peginterferon alfa-2a | $11M |
| tenofovir disoproxil fumarate | $9.1M |
| entecavir | $7.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 5 technologies for this condition, recommending 3 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tenofovir alafenamideTenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | terminated | 2017-03 |
| tenofovir disoproxilTenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | recommended | 2009-07 |
| entecavirEntecavir for the treatment of chronic hepatitis B | TA153 | recommended | 2008-08 |
| telbivudineTelbivudine for the treatment of chronic hepatitis B | TA154 | not recommended | 2008-08 |
| adefovir dipivoxil and peginterferon alfa 2aAdefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | recommended | 2006-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.